Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3BHN1)

Drug Name

Etomoxir Drug Info

Synonyms

ETOMOXIR; 82258-36-4; rac- Etomoxir; Etomoxirum [Latin]; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate; BRN 4496620; Oxiranecarboxylic acid, 2-(6-(4-chlorophenoxy)hexyl)-, ethyl ester; B 807-54; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxiranecarboxylate; Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS]; Etomoxirum; etomoxir[inn]; SMR000449321; Rac-Etomoxir Ethyl Ester; C17H23ClO4; ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate; etoxomir; AC1L3XCY; MLS001424024; MLS000758228; SCHEMBL681359

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Terminated	[1]

Cross-matching ID

PubChem CID: 9840324
ChEBI ID: CHEBI:95011
CAS Number: CAS 124083-20-1
TTD Drug ID: DM3BHN1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Carnitine O-palmitoyltransferase I (CPT1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[2]
Perhexiline	DMINO7Z	Angina pectoris	BA40	Approved	[3]
SDZ-CPI-975	DM70MJQ	Diabetic complication	5A2Y	Discontinued in Phase 1	[4]
DB-200	DMTXPSB	Psoriasis vulgaris	EA90	Terminated	[5]
C75	DMHGX1N	Obesity	5B81	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carnitine O-palmitoyltransferase I (CPT1B)	TTDL0NY	CPT1B_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
2	Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
3	Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
4	Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
5	Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.
6	C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.